When was Knopp Biosciences founded?

Knopp Biosciences was founded in 2005 and raised its 1st funding round 1 year after it was founded.

Where is Knopp Biosciences located?

Knopp Biosciences is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania.

Is Knopp Biosciences a funded company?

Knopp Biosciences is a funded company, having raised a total of $194M across 15 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2006.

When was the latest funding round of Knopp Biosciences?

Knopp Biosciences' latest funding was a $***** Grant (prize money) round on Oct 20, 2021, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.67B in funding in 2026 to date.

Where does Knopp Biosciences rank among its competitors?

Knopp Biosciences ranks 146th amongst 537 active competitors, of which 168 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Knopp Biosciences?

Knopp Biosciences' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Knopp Biosciences - 2026 Company Profile, Funding & Competitors

Knopp Biosciences is a series D company based in Pittsburgh (United States), founded in 2005. It operates as a Developer of small-molecule therapeutics for the treatment of CNS and inflammatory diseases. Knopp Biosciences has raised $194M in funding from investors like Innovation Works, Kramer Capital Partners and LaunchCyte. The company has 537 active competitors, including 168 funded and 126 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Knopp Biosciences is a developer of small-molecule therapeutics for the treatment of CNS and inflammatory diseases. It's lead candidate dexpramipexole targets mitochondrial function has completed phase II trials for hypereosinophilic syndrome, chronic rhinosinusitis and Amyotrophic lateral sclerosis. In addition, the company is evaluating further candidates for neuropathic pain and epilepsy.

Website: knoppbio.com
Registered Address: Pittsburgh, Pennsylvania

Key Metrics

Founded Year

2005

Location

Pittsburgh, United States

Stage

Series D

Total Funding

$194M in 15 rounds

Latest Funding Round

Grant (prize money), Oct 20, 2021, $*****

Investors

Innovation Works & 8 more

Ranked

146^th among 537 active competitors

Similar Companies

Keros Therapeutics & 50 more

View Knopp Biosciences' full profile

Knopp Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Knopp Biosciences Llc CIN: 272910593 , United States, Active	Dec 26, 999	-	23 (As on Dec 31, 2021)	-

Knopp Biosciences has raised a total funding of $194M over 15 rounds. Its first funding round was on 2006. Its latest funding round was a Grant (prize money) round on Oct 20, 2021 for $*****. 1 investor participated in its latest round. Knopp Biosciences has 9 institutional investors.

Here is the list of recent funding rounds of Knopp Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 20, 2021	1639419	Grant (prize money)	9727122	5080000	4241377	9568224
Nov 11, 2020	6844763	Series D	3043729	3670267	4476023	5441099
Oct 27, 2020	9776794	Series D	2866468	8233188	3388423	9204400

Access funding benchmarks and valuations. Sign up today!

View details of Knopp Biosciences's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Knopp Biosciences include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Knopp Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	69/100
5th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
6th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
7th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100
8th	Neumora 2020, Watertown (United States), Public	Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders	$612M	Arch Venture Partners, Mubadala & 19 others	67/100
9th	Keros Therapeutics 2016, Lexington (United States), Public	Developer of small molecules to treat hematologic and musculoskeletal disorders	$90M	Foresite Capital, Pontifax & 9 others	66/100
10th	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
146th	Knopp Biosciences 2005, Pittsburgh (United States), Series D	Developer of small-molecule therapeutics for the treatment of CNS and inflammatory diseases	$194M	Biogen, Saturn Partners & 7 others	43/100